Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Micro Ribonucleic Nucleic Acid Panel Assays Launched

By LabMedica International staff writers
Posted on 28 Sep 2015
A novel approach has been developed by combinations of micro ribonucleic nucleic acid (miRNA) specific reverse transcriptase and hemi-nested real-time polymerase chain reaction (PCR) primers that have been designed to maximize miRNA detection sensitivity and specificity.

The miRNA Panel Assays provide scientists with a convenient way to quickly analyze miRNAs that suggest a correlation with the dysregulations in various cancers, in maintenance, differentiation and reprogramming of stem cells and to look at circulating miRNAs that are regarded as a promising new class of biomarkers.

The real-time PCR assays use SensiSMART with SYBR Green (Bioline USA Inc.; Taunton, MA, USA) to enable detection of extremely low levels of miRNA with high specificity, allowing the discrimination between closely related miRNA sequences. More...
This highly reproducible, sensitive platform has been validated independently by molecular diagnostic and pharmaceutical laboratories and showed superior performance to existing commercial assays.

The Bioline EPIK miRNA Panel Assays were developed for miRNA profiling of cancer samples, biofluids, and stem cells. The EPIK miRNA Panel Assays are the result of collaboration with MiRXES (Singapore). Marco Calzavara, president of Bioline, said, “The release of the EPIK miRNA Panel Assays follows the release of the ISOLATE II miRNA, Biofluids RNA, RNA/DNA/Protein and FFPE RNA/DNA Kits earlier this year and shows the continued commitment of Bioline to produce high quality miRNA kits to help researchers with miRNA expression profiling and quantification and in biomarker discovery.”

Richard L. Eberly, president of Meridian Life Science, Inc. (Cincinnati, OH, USA), the parent company, stated, "We are excited about the release of the EPIK miRNA Panel Assays and the enhanced performance they provide for our important life science customers in the molecular diagnostic and pharmaceutical laboratories and biotechnology companies. We remain committed to the continued expansion of the rapidly growing portfolio of highly specialized molecular biology products from Bioline.”

Related Links:

Bioline USA Inc.
MiRXES 
Meridian Life Science, Inc.



Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
HPV Test
Allplex HPV28 Detection
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Illustration of the new blood test, which uses a DNA chip to detect the tumor’s biological fingerprint (Photo courtesy of Tel Aviv University)

Blood Test on a Chip Offers Low-Cost Lung Cancer Detection Without DNA Sequencing

Lung cancer is the leading cause of cancer deaths worldwide, and screening often yields indeterminate results that prompt invasive workups. Computed tomography (CT) detects small nodules but can flag benign... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.